Literature DB >> 9083336

Metabolic studies of human primitive neuroectodermal tumour cells by proton nuclear magnetic resonance spectroscopy.

C L Florian1, T Pietsch, M Noble, S R Williams.   

Abstract

Well-characterized cell lines established from primitive neuroectodermal tumours (PNETs) were examined by proton nuclear magnetic resonance (1H-NMR) spectroscopy and chromatographic analysis of perchloric acid extracts, following amplification in cell culture. A characteristic 1H-NMR spectroscopic metabolite pattern was found for medulloblastoma cell lines, which clearly discriminates these cells from PNETs of other locations in the central nervous system (CNS), on the basis of their N-acetyl aspartate (NAA) and aspartate expression. Medulloblastoma cell lines were heterogeneous in respect of their metabolite expression, possibly owing to the heterogeneity in their differentiation along lineages of the CNS. All PNET spectra displayed similar features, including decreased NAA and creatine peaks and increased signals from choline compounds (Cho) compared with normal cerebellum. The expression of NAA by the medulloblastoma lines was in the opposite order to the extent of neuronal differentiation, which may indicate their origin from a progenitor cell with the phenotype of an oligodendrocyte-type-2 astrocyte cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083336      PMCID: PMC2222751          DOI: 10.1038/bjc.1997.173

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  1H NMR detection of cerebral myo-inositol.

Authors:  S Cerdàn; R Parrilla; J Santoro; M Rico
Journal:  FEBS Lett       Date:  1985-07-22       Impact factor: 4.124

2.  Medulloblastoma. An immunohistological study of 50 cases.

Authors:  F F Cruz-Sanchez; M L Rossi; J T Hughes; M M Esiri; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.

Authors:  H S Friedman; P C Burger; S H Bigner; J Q Trojanowski; C J Wikstrand; E C Halperin; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

4.  High-resolution one- and two-dimensional 1H MRS of human brain tumor and normal glial cells.

Authors:  K Kotitschke; H Jung; S Nekolla; A Haase; A Bauer; U Bogdahn
Journal:  NMR Biomed       Date:  1994-05       Impact factor: 4.044

5.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

6.  Developmental changes of N-acetyl-L-aspartic acid, N-acetyl-alpha-aspartylglutamic acid and beta-citryl-L-glutamic acid in different brain regions and spinal cords of rat and guinea pig.

Authors:  M Miyake; Y Kakimoto
Journal:  J Neurochem       Date:  1981-10       Impact factor: 5.372

7.  Differentiation in the medulloblastoma. A histological and immunohistochemical study.

Authors:  P C Burger; F C Grahmann; A Bliestle; P Kleihues
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

8.  Revision of the World Health Organization classification of brain tumors for childhood brain tumors.

Authors:  L B Rorke; F H Gilles; R L Davis; L E Becker
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

9.  Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice.

Authors:  P F Jacobsen; D J Jenkyn; J M Papadimitriou
Journal:  J Neuropathol Exp Neurol       Date:  1985-09       Impact factor: 3.685

10.  Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors.

Authors:  H Bruhn; J Frahm; M L Gyngell; K D Merboldt; W Hänicke; R Sauter; C Hamburger
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

View more
  1 in total

1.  Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress.

Authors:  Nam Hee Kim; Yong Hoon Cha; Jueun Lee; Seon-Hyeong Lee; Ji Hye Yang; Jun Seop Yun; Eunae Sandra Cho; Xianglan Zhang; Miso Nam; Nami Kim; Young-Su Yuk; So Young Cha; Yoonmi Lee; Joo Kyung Ryu; Sunghyouk Park; Jae-Ho Cheong; Sang Won Kang; Soo-Youl Kim; Geum-Sook Hwang; Jong In Yook; Hyun Sil Kim
Journal:  Nat Commun       Date:  2017-02-08       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.